A second-generation TKI should always be used as initial therapy for CML
Author:
Affiliation:
1. Department of Leukemia, MD Anderson Cancer Center, Houston, TX
Abstract
Publisher
American Society of Hematology
Subject
Hematology
Link
http://ashpublications.org/bloodadvances/article-pdf/2/24/3653/1554980/advances018655.pdf
Reference20 articles.
1. Long-term outcomes of imatinib treatment for chronic myeloid leukemia;Hochhaus;N Engl J Med,2017
2. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial;Cortes;J Clin Oncol,2018
3. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial;Cortes;J Clin Oncol,2016
4. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial;Hochhaus;Leukemia,2016
5. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials;Sasaki;Lancet Haematol,2015
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Challenges in management of older patients with chronic myeloid leukemia;Leukemia & Lymphoma;2024-04-23
2. The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia;Pathology - Research and Practice;2024-02
3. An Update on the Management of Advanced Phase Chronic Myeloid Leukemia;Current Hematologic Malignancy Reports;2023-08-31
4. Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT;American Journal of Hematology;2022-10-31
5. Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia;Leukemia;2022-10-29
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3